A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

ObjectivesThe Kirsten Rat Sarcoma (KRAS) mutation is the commonest oncogenic drive mutation in lung adenocarcinoma (LUAD) and immunotherapy may be quite promising for KRAS-mutant LUAD. While the effects of tumor mutation burden (TMB) and copy number alteration (CNA) are poorly understood in this ill...

Full description

Bibliographic Details
Main Authors: Luochengling Xiang, Xiao Fu, Xiao Wang, Wenyuan Li, Xiaoqiang Zheng, Kejun Nan, Tao Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
KRAS mutation
lung adenocarcinoma
tumor mutation burden
copy number of alteration
biomarker
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.559896/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.559896/full

Similar Items